These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 15691616

  • 1. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
    Sato A, Hayashi K, Saruta T.
    Am J Hypertens; 2005 Jan; 18(1):44-9. PubMed ID: 15691616
    [Abstract] [Full Text] [Related]

  • 2. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 3. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F.
    J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
    [Abstract] [Full Text] [Related]

  • 4. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
    Taira M, Toba H, Murakami M, Iga I, Serizawa R, Murata S, Kobara M, Nakata T.
    Eur J Pharmacol; 2008 Jul 28; 589(1-3):264-71. PubMed ID: 18582458
    [Abstract] [Full Text] [Related]

  • 5. Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease.
    Sengul E, Sahin T, Sevin E, Yilmaz A.
    Ren Fail; 2009 Jul 28; 31(10):928-32. PubMed ID: 20030528
    [Abstract] [Full Text] [Related]

  • 6. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
    Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ.
    Clin J Am Soc Nephrol; 2006 Mar 28; 1(2):256-62. PubMed ID: 17699214
    [Abstract] [Full Text] [Related]

  • 7. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months.
    González Monte E, Andrés A, Polanco N, Toribio MJ, Santana R, Gutiérrez Martínez E, González J, Ramírez E, Hernández A, Morales E, Praga M, Morales JM.
    Transplant Proc; 2010 Oct 28; 42(8):2899-901. PubMed ID: 20970564
    [Abstract] [Full Text] [Related]

  • 8. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J, Fraccarollo D.
    Minerva Cardioangiol; 2003 Apr 28; 51(2):155-64. PubMed ID: 12783071
    [Abstract] [Full Text] [Related]

  • 9. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L, Kocks MJ, Laverman GD, Navis G.
    Minerva Med; 2004 Oct 28; 95(5):395-409. PubMed ID: 15467515
    [Abstract] [Full Text] [Related]

  • 10. The effects of spironolactone on nephron function in patients with diabetic nephropathy.
    Ustundag A, Tugrul A, Ustundag S, Sut N, Demirkan B.
    Ren Fail; 2008 Oct 28; 30(10):982-91. PubMed ID: 19016150
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S.
    Acta Med Indones; 2008 Jan 28; 40(1):34-7. PubMed ID: 19054878
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
    Navarro JF, Mora C, Muros M, García J.
    J Am Soc Nephrol; 2005 Jul 28; 16(7):2119-26. PubMed ID: 15917336
    [Abstract] [Full Text] [Related]

  • 15. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
    Agarwal R, Siva S, Dunn SR, Sharma K.
    Am J Kidney Dis; 2002 Mar 28; 39(3):486-92. PubMed ID: 11877567
    [Abstract] [Full Text] [Related]

  • 16. Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease.
    Guney I, Selcuk NY, Altintepe L, Atalay H, Başarali MK, Büyükbaş S.
    Ren Fail; 2009 Mar 28; 31(9):779-84. PubMed ID: 19925284
    [Abstract] [Full Text] [Related]

  • 17. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
    Tschöpe C, Seidl U, Reinecke A, Riester U, Graf K, Schultheiss HP, Hilgenfeldt U, Unger T.
    Int Immunopharmacol; 2003 Mar 28; 3(3):335-44. PubMed ID: 12639811
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness of aldosterone blockade in patients with diabetic nephropathy.
    Sato A, Hayashi K, Naruse M, Saruta T.
    Hypertension; 2003 Jan 28; 41(1):64-8. PubMed ID: 12511531
    [Abstract] [Full Text] [Related]

  • 19. Spironolactone and ACE inhibition in chronic renal failure.
    Almirall J, Lopez T.
    N Engl J Med; 2002 Feb 07; 346(6):456-7. PubMed ID: 11837270
    [No Abstract] [Full Text] [Related]

  • 20. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
    Katavetin P, Eiam-Ong S, Suwanwalaikorn S.
    J Med Assoc Thai; 2006 Feb 07; 89(2):170-7. PubMed ID: 16579002
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.